128 results
NT 10-Q
IPIX
Innovation Pharmaceuticals Inc.
15 Nov 23
Notice of late quarterly filing
8:00am
September 30, 2023 of $0.9 million, as compared to $1.4 million for the three months ended September 30, 2022, largely as a result of decreased research … and development expenses (approximately $0.3 million for the three months ended September 30, 2023 compared to $0.9 million for the three months ended
8-K
EX-99.1
q82w8ihi5f
15 Jun 22
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-10.1
dgbuef
15 Jun 22
Entry into a Material Definitive Agreement
4:00pm
NT 10-Q
v1dbs3tcga
17 Feb 21
Notice of late quarterly filing
8:00am
8-K
EX-99.1
ku60g1k
15 Jan 21
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives
12:35pm
8-K
EX-99.1
t8axdjj tgbfm3
22 Dec 20
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
9:00am
8-K
EX-10.1
5xyq1dx
10 Dec 20
Entry into a Material Definitive Agreement
12:00am
8-K
1ib4m
10 Dec 20
Entry into a Material Definitive Agreement
12:00am
424B5
9e4svjdlgrt43h
10 Dec 20
Prospectus supplement for primary offering
12:00am